Clinical Evidence for Non-Diabetic GLP-1 Use The STEP trials (Semaglutide Treatment Effect in People with Obesity) enrolled participants without diabetes and demonstrated average weight loss of 1522% over 68 weeks compared to placebo
106 Two additional clinical trials are being conducted to gather more data on adverse effects in different situations of liver injury, and a phase 2 trial investigating treatment effects for MASH with fibrosis based on histological assessment is ongoing (NCT05877547)
Closing Thoughts AOD 9604 and Tesamorelin are two promising peptides under study for their possible roles in fat loss and metabolic health
But studies also show a quarter of the once-hopeful abandon their goals within the first week, and more than half quit by Feb
Coverage depends on the drug and your insurance plandiabetes use is often covered, but weight loss may not be
Other major metabolites in the human include aflatoxicol (AFL), AFLH1, AFB2 and AFB 1 -2, 2-dihydrodiol [80]